Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
18 results
  • Head and Neck Cancer

24-269          Phase III

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS =20) (HexAgon-HN)

  • Rectal Cancer, Thymoma, Ovarian Cancer, Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers

  • Ovarian Cancer, Metastatic/Advanced Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Endometrial Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer

23-618          Phase I

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

  • Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Metastatic/Advanced Cancer

22-614          Phase I

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

  • Head and Neck Cancer, Lung Cancer, Melanoma, Liver Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer

24-203          Phase I

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

  • Head and Neck Cancer, Endometrial Cancer, Breast Cancer, Ovarian Cancer

23-044          Phase II

First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

  • Head and Neck Cancer, Breast Cancer, Bladder Cancer, Colorectal Cancer, Lung Cancer, Melanoma

22-405          Phase II

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

  • Thyroid Cancer, Head and Neck Cancer

22-018          Phase II

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)

Showing 11 - 18 of 18 results